← Eichor
Study identifier: NCT07669584 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

PKB171 Against Placebo in Couples With Mild Male Factor Infertility

Condition: Infertility Due to Azoospermia  ·  Sponsor: Prokrea BCN, S.L.

PhasePhase 2/Phase 3
Planned participants732
Who can joinAll sexes, 18 Years to 38 Years
Healthy volunteersNo

About this study

The test medication Gel PKB171 is a vaginal gel that has not yet been licensed by the regulatory authorities. However, the active substance pentoxifylline has been available as tablets for decades and is used to increase peripheral blood flow in patients with circulation problems. Additionally, pentoxifylline is used to treat sperm samples in artificial insemination and test tube fertilisation to increase the mobility of sperm. A phase I clinical trial, 30 women were treated with Gel PKB171 for up to three times. Gel PKB171 was generally well tolerated and the most common side effects were local reactions like vaginal discharge and itching. A phase II clinical trial, investigate the efficacy and safety of two concentrations of PKB171 versus placebo in couples with asthenozoospermia who wish to conceive. A total of 72 couples were planned to be included in the study. Finally, 28 couples were enrolled, and 11 couples were randomised. Within this trial, two concentrations of pentoxifylline gel were compared (5 mL of gel PKB171 containing 150 mg (3%) of pentoxifiylline, and 5 mL of gel PKB171 containing and 200 mg (4%) of pentoxifylline. Both doses were tolerated well and revealed no safety concerns as assessed by AEs, local Gel PKB171 tolerability, laboratory parameters, vital signs, gynaecologic and physical examination, or transvaginal ultrasound findings. This study was prematurely discontinued due to low numbers of eligible subjects and high recruitment failure rates, desp…

This description comes directly from the study's public registry record.

Talk to the study team

Elena Vernet Arias, MD, PhD  ·  +34 661 378 408  ·  elena@prokreabcn.com

Miquel Raurell, MD  ·  +34 93 417 09 11  ·  miquel@prokreabcn.com

Always discuss trial participation with your own doctor first.

Locations (12)

Clinica Universidad de NavarraPamplona, Navarre, SpainRecruiting
Hospital del MarBarcelona, SpainRecruiting
Clinica FerttyBarcelona, SpainNot Yet Recruiting
Clinica Sagrada FamiliaBarcelona, SpainRecruiting
Assir Dreta-Cap Pare ClaretBarcelona, SpainNot Yet Recruiting
Assir Dreta-Cap Roger de FlorBarcelona, SpainNot Yet Recruiting
Hospital de la Santa Creu i Sant PauBarcelona, SpainNot Yet Recruiting
HM Gabinete Médico VelázquezMadrid, SpainNot Yet Recruiting
Hospital Universitario San RafaelMadrid, SpainRecruiting
Clinica Universidad de NavarraMadrid, SpainRecruiting
Hospital Universitario L PazMadrid, SpainNot Yet Recruiting
Hospital Universitario Nuestra Señora de ValmeSeville, SpainRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07669584